novo nordisk cagrilintide files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management Novo Nordisk: Obesity drug CagriSema

There is no human clinical evidence demonstrating superior results at higher doses

Whether after a fracture or a joint replacement, BPC-157 can significantly improve joint healing time and reduce discomfort, helping patients regain strength and mobility faster

Annals of Clinical and Laboratory Science (2015) 6

(Source) When this enzyme is present in great concentration within fat cells and is highly expressed, obesity is inevitable: In the study by Kannt and colleagues, NNMT expression is increased ~2-fold in subcutaneous and omental adipose tissue of type 2 diabetic subjects (men and women), compared to healthy controls Importantly, interventions that increase insulin sensitivity, such as exercise and bariatric surgery, also decreased expression of NNMT in adipose tissue For this reason alone, scientists have been interested in every possible method for inhibiting NNMT expression: We report that NNMT expression is increased in [white adipose tissue (WAT)] and liver of obese and diabetic mice

Rated 4.5/5 by 54 verified customers 70mg (10mg/10mg/50mg) Ships Today if ordered within 1 hr 33 min

BPC-157 stable gastric pentadecapeptide: novel therapy for wound healing and tissue repair Life Sciences Seiwerth S et al